Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myeloma

Abstract

Treatment advances in multiple myeloma (MM) increased the proportion of patients achieving complete response (CR) over the past decades. [1][2][3] This progress prompted an evolution of the definition of response, and measurable residual disease (MRD) testing is now being recognized as a strong and dynamic prognostic indicator in MM. [4][5][6][7][8][9][10][11] In this regard, MRD has been incorporated into the International Myeloma Working Group (IMWG) response criteria and is being developed as a clinical end-point in reports of trial outcomes. [12][13][14][15] The IMWG response criteria on MRD assessment utilized a minimum cut-off of one malignant cell in at least 10 5 bone-marrow (BM) nucleated cells for defining

Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside

“…The Lymphotrack assay was established by combining the basic strategy of BIOMED-2 and NGS technology. After input, the compatible FASTQ files can be processed into fully analyzed data by the corresponding application Lymphotrack DataAnalysis [ 86 ]. Productive rearrangements were further analyzed for parse, re-organization, and exportation using algorithms.…”